STING Agonist Payload for Antibody Drug Conjugates
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current antibody-drug conjugates lack effective payloads that can selectively target and activate the STING pathway for enhanced immunotherapy, particularly in cancer treatment, where precise activation of interferon and cytokine production is needed.
Innovation Solution
A compound-linker conjugate of formula (I) is developed, which includes specific structural components that can be used as payloads in antibody-drug conjugates, allowing for targeted delivery and activation of the STING pathway by recognizing and mimicking endogenous DNA, thereby triggering interferon production.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Adaptability or versatility
If antibody-drug conjugates use conventional cytotoxic payloads, then they can achieve targeted delivery to tumor cells, but they lack the ability to selectively activate the STING pathway for enhanced immunotherapy
Solution Approach 1:
The patent modifies the chemical structure of small-molecule STING agonists by introducing specific functional groups and molecular configurations that enable selective STING pathway activation. The compound structure includes key pharmacophoric elements that bind to STING with high affinity and selectivity, transforming conventional cytotoxic payloads into immunotherapeutic agents that trigger interferon production and immune response.
2Reliability
If the compound-linker conjugate is designed for high STING pathway activation, then interferon and cytokine production is enhanced, but the complexity of the payload structure increases
Solution Approach 1:
The compound-linker conjugate is divided into distinct functional modules: a STING agonist core structure that provides selective pathway activation, a linker component that enables controlled release, and targeting moieties that facilitate antibody conjugation. This segmentation allows each component to perform its specific function while maintaining overall structural manageability and synthetic feasibility.
3Ease of operation
If conventional payloads are used in antibody-drug conjugates, then they can be selectively delivered to target sites, but they cannot trigger interferon production and cytokine release through STING pathway activation
Solution Approach 1:
The compound-linker conjugate is designed to perform multiple functions within a single molecular entity: it maintains the ability for targeted delivery to tumor cells through antibody conjugation, simultaneously provides selective STING pathway activation, and triggers interferon production and cytokine release. This multi-functionality transforms the payload from a simple cytotoxic agent into a comprehensive immunotherapeutic tool.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The compound-linker conjugate enables selective activation of the STING pathway, enhancing interferon and cytokine production, which can lead to improved therapeutic outcomes in cancer treatment by providing a targeted and potent immunotherapeutic approach.
Implementation Method 1
allowing for targeted delivery and activation of the STING pathway by recognizing and mimicking endogenous DNA
Data Source
AI summary
Disclosed are a compound-linker conjugate and a class of compounds having the STING activation activity, as well as their applications in the preparation of antibody drug conjugates. The compound-linker conjugate is represented byThe compounds are represented byThe compounds are suitable as payloads of the antibody drug conjugates.